Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Majadahonda – page 95

3 275 clinical trials in Majadahonda, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Majadahonda at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Majadahonda

Open in trial search

Phase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Summit Therapeutics Inc.

Lichen planopilaris

Not yet recruiting

Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Parkinson's disease

Not yet recruiting

Efficacy and Safety of Carbidopa/Levodopa (CP-012B) in Participants with Parkinson’s Disease with Early Morning OFF Episodes

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Carbidopa
  • Sponsor:Contera Pharma A/S

Dermatitis atopic

Not yet recruiting

Efficacy of comekibart Injection in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Hunan Mabgeek Biotech Co. Ltd.

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Majadahonda

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on ATTR amyloid cardiomyopathy, evaluating new therapeutic approaches for both hereditary and wild-type variants of this heart condition.

  • Heart Disease Management
  • Cardiac Function Assessment
  • Disease Markers Evaluation

Multiple trials testing novel compounds to improve patient outcomes and quality of life.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting urinary tract infections and various herpes virus strains, including studies on both prevention and treatment.

  • UTI Prevention
  • Herpes Zoster Protection
  • Immunotherapy Development

Focus on long-term efficacy and immune response in different age groups.

03 Oncology Studies

Advanced research in multiple cancer types, including prostate cancer, gastric cancer, and lymphomas, with emphasis on targeted therapies and combination treatments.

  • Metastatic Disease Treatment
  • Novel Drug Combinations
  • Immunotherapy Approaches

Investigating breakthrough treatments for various stages of cancer progression.

04 Neurological Disorders

Pioneering research in cerebral ischemic stroke and multiple sclerosis, evaluating innovative treatments to improve patient outcomes and disease management.

  • Stroke Treatment
  • Progressive MS Management
  • Functional Recovery

Focus on both acute interventions and long-term disease modification.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.